MTOR and neoplasm: Aberrant activation of the pathway defined by phosphatidylinositol 3-kinase (PI3K), Akt (protein kinase B), and mammalian target of rapamycin (mTOR) has been observed across a wide range of neoplastic diseases [1–4].